1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Left atrial (LA) structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF) is only established in small studies. Therefore, we conducted a systematic review of LA structure and function in order to find differences between patients with HFrEF and HFpEF. English literature on LA structure and function using echocardiography was reviewed to calculate pooled prevalence and weighted mean differences (WMD). A total of 61 studies, comprising 8806 patients with HFrEF and 9928 patients with HFpEF, were included. The pooled prevalence of atrial fibrillation (AF) was 34.4% versus 42.8% in the acute inpatient setting, and 20.1% versus 33.1% in the chronic outpatient setting when comparing between HFrEF and HFpEF. LA volume index (LAVi), LA reservoir global longitudinal strain (LAGLS R), and E/e’ was 59.7 versus 52.7 ml/m 2, 9.0% versus 18.9%, and 18.5 versus 14.0 in the acute inpatient setting, and 48.3 versus 38.2 ml/m 2, 12.8% versus 23.4%, and 16.9 versus 13.5 in the chronic outpatient setting when comparing HFrEF versus HFpEF, respectively. The relationship between LAVi and LAGLS R was significant in HFpEF, but not in HFrEF. Also, in those studies that directly compared patients with HFrEF versus HFpEF, those with HFrEF had worse LAGLS R [WMD = 16.3% (22.05,8.61); p < 0.001], and higher E/e’ [WMD = −0.40 (−0.56, −0.24); p < 0.05], while LAVi was comparable. When focusing on acute hospitalized patients, E/e’ was comparable between patients with HFrEF and HFpEF. Despite the higher burden of AF in HFpEF, patients with HFrEF had worse LA global function. Left atrial myopathy is not specifically related to HFpEF.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s10741-021-10204-8.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: not found
          • Article: not found

          Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Neurohormonal activation in heart failure with reduced ejection fraction

            Heart failure with reduced ejection fraction (HFrEF) develops when cardiac output falls as a result of cardiac injury. The most well-recognized of the compensatory homeostatic responses to a fall in cardiac output are activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS). In the short term, these 'neurohormonal' systems induce a number of changes in the heart, kidneys, and vasculature that are designed to maintain cardiovascular homeostasis. However, with chronic activation, these responses result in haemodynamic stress and exert deleterious effects on the heart and the circulation. Neurohormonal activation is now known to be one of the most important mechanisms underlying the progression of heart failure, and therapeutic antagonism of neurohormonal systems has become the cornerstone of contemporary pharmacotherapy for heart failure. In this Review, we discuss the effects of neurohormonal activation in HFrEF and highlight the mechanisms by which these systems contribute to disease progression.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.

              The purpose of this study was to examine the prevalence of abnormalities in cardiac structure and function present in patients with heart failure and a preserved ejection fraction (HFPEF) and to determine whether these alterations in structure and function were associated with cardiovascular morbidity and mortality. The Irbesartan in HFPEF trial (I-PRESERVE) enrolled 4128 patients; echocardiographic determination of left ventricular (LV) volume, mass, left atrial (LA) size, systolic function, and diastolic function were made at baseline in 745 patients. The primary end point was death or protocol-specific cardiovascular hospitalization. A secondary end point was the composite of heart failure death or heart failure hospitalization. Associations between baseline structure and function and patient outcomes were examined using univariate and multivariable Cox proportional hazard analyses. In this substudy, LV hypertrophy or concentric remodeling was present in 59%, LA enlargement was present in 66%, and diastolic dysfunction was present in 69% of the patients. Multivariable analyses controlling for 7 clinical variables (including log N-terminal pro-B-type natriuretic peptide) indicated that increased LV mass, mass/volume ratio, and LA size were independently associated with an increased risk of both primary and heart failure events (all P<0.05). Left ventricular hypertrophy or concentric remodeling, LA enlargement, and diastolic dysfunction were present in the majority of patients with HFPEF. Left ventricular mass and LA size were independently associated with an increased risk of morbidity and mortality. The presence of structural remodeling and diastolic dysfunction may be useful additions to diagnostic criteria and provide important prognostic insights in patients with HFPEF.
                Bookmark

                Author and article information

                Contributors
                j.p.van.melle@umcg.nl
                Journal
                Heart Fail Rev
                Heart Fail Rev
                Heart Failure Reviews
                Springer US (New York )
                1382-4147
                1573-7322
                26 January 2022
                26 January 2022
                2022
                : 27
                : 5
                : 1933-1955
                Affiliations
                [1 ]GRID grid.419385.2, ISNI 0000 0004 0620 9905, National Heart Centre Singapore, ; Singapore, Singapore
                [2 ]GRID grid.4830.f, ISNI 0000 0004 0407 1981, Department of Cardiology, , University of Groningen, University Medical Centre Groningen, ; Hanzeplein 1, 9700 RB Groningen, the Netherlands
                [3 ]GRID grid.428397.3, ISNI 0000 0004 0385 0924, Duke-NUS Medical School, ; Singapore, Singapore
                [4 ]GRID grid.413593.9, ISNI 0000 0004 0573 007X, Division of Cardiology, Department of Internal Medicine, , Mackay Memorial Hospital, ; Taipei, Taiwan
                [5 ]GRID grid.16872.3a, ISNI 0000 0004 0435 165X, Department of Dermatology, , Netherlands Institute for Pigment Disorder/Amsterdam Infection & Immunity Institute; Cancer Center Amsterdam, ; Amsterdam, the Netherlands
                [6 ]GRID grid.452449.a, ISNI 0000 0004 1762 5613, Institute of Biomedical Sciences, , Mackay Medical College, ; New Taipei City, Taiwan
                Article
                10204
                10.1007/s10741-021-10204-8
                9388424
                35079942
                679c4ffe-3d21-4767-b0de-3904eea8297d
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 9 December 2021
                Categories
                Article
                Custom metadata
                © Springer Science+Business Media, LLC, part of Springer Nature 2022

                Cardiovascular Medicine
                la structure,function,hfref,hfpef
                Cardiovascular Medicine
                la structure, function, hfref, hfpef

                Comments

                Comment on this article